Jun­shi, Co­herus gun for ma­jor PD-(L)1 mar­ket with PhI­II NSCLC re­sults

As a slate of made-in-Chi­na check­point in­hibitors ar­rive on the scene, Chi­na-based drug­mak­ers have shown time and again that they’re not con­tent with just the Chi­nese mar­ket or nich­es of the Amer­i­can mar­ket. Rather, they are more than ea­ger to fol­low the sprawl­ing roadmap that lead­ers like Mer­ck and Bris­tol My­ers Squibb have of­fered — and dive right in­to large can­cer in­di­ca­tions.

For the lat­est ex­am­ple, look no fur­ther than Shang­hai Jun­shi — the first biotech to steer a home­grown PD-(L)1 to­ward ap­proval from Chi­na’s NM­PA.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.